Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2

Documenti analoghi

• Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
  di: Clark, Joseph I, et al.
  Pubblicazione: (2015)
• The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)
  di: Kaufman, Howard L., et al.
  Pubblicazione: (2014)
• High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates
  di: Wong, Michael K, et al.
  Pubblicazione: (2013)
• Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
  di: Wong, Michael KK, et al.
  Pubblicazione: (2015)
• Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes
  di: Wong, Michael K, et al.
  Pubblicazione: (2014)